HUMAN PERIPHERAL BLOOD HEMATOPOIETIC PROGENITOR CELL

Name: HUMAN PERIPHERAL BLOOD HEMATOPOIETIC PROGENITOR CELL in Bone Marrow Transplant (BMT)
Creator: Floatz
License: https://terminal.floatz.ai/terms

Bone Marrow Transplant (BMT)

Ossium Health, Inc.Cell therapyActive

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 95/ 100

Competitive context

74 Active assets in the Bone Marrow Transplant (BMT) cohort.

Asset / Sponsor	Phase	Rating
Busulphan Institute of Hematology & Blood Diseases Hospital, China	Phase 3	BBB
Cyclophosphamide The First Affiliated Hospital of Soochow University	Phase 3	BBB
FILGRASTIM National Cancer Institute (NCI)	Phase 2/3	BBB
Cyclophosphamide St. Jude Children's Research Hospital	Phase 3	BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER M.D. Anderson Cancer Center	Phase 2	BBB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →